Recent progress in gene transfer into hematopoietic stem cells

Critical Reviews in Oncology/Hematology

Volumn 30, Issue 2, 1999, Pages 143-158

  Lutzko, Carolyn ^a,c   Dubé, Ian D ^a,b,c   Stewart, A Keith ^b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b Hematol/Oncol Gene Therapy Program   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; CELL SELECTION; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LENTIVIRINAE; MARKER GENE; NONHUMAN; RETROVIRUS; REVIEW; TRANSGENE; VIRUS CELL INTERACTION; VIRUS RECOMBINANT;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 0032901068     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00043-2     Document Type: Review

References (199)

1. Rosenberg S.A., Aebersold P., Cornetta K. et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction [see comments]. New. Engl. J. Med. 323:1990;570-578.
2. Anderson W.F. Human gene therapy. Science. 256:1992;808-813.
3. Miller A.D. Human gene therapy comes of age. Nature. 357:1992;455-460.
4. Mulligan R.C. The basic science of gene therapy. Science. 260:1993;926-932.
5. Cai Q., Rubin J.T., Lotze M.T. Genetically marking human cells - results of the first clinical gene transfer studies. Cancer. Gene. Ther. 2:1995;125-136.
6. Blaese R.M., Culver K.W., Miller A.D. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 270:1995;475-480.
7. Ross G., Erickson R., Knorr D. et al. Gene therapy in the US: a 5-year status report. Hum. Gene. Ther. 7:1996;1781-1790.
8. Abramson S., Miller R.G., Phillips R.A. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J. Exp. Med. 145:1977;1567-1579.
9. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 81:1993;2844-2853.
10. Phillips R.A. Stem-cell heterogeneity: pluripotent and committed stem cells ofthe myeloid and lymphoid systems. Clarkson B. Differentiation of normal and neoplastic hematopoietic cells. 1978;109-120 Cold Spring Harbor Laboratory, Cold Spring Harbor.
11. Amenomori T., Honda T., Otake M. et al. Growth and differentiation of circulating hemopoietic stem cells with atomic bomb irradiation-induced chromosome abnormalities. Exp. Hematol. 16:1988;849-854.
12. Kusunoki Y., Kodama Y., Hirai Y. et al. Cytogenetic and immunologic identification of clonal expansion of stem cells into T and B lymphocytes in one Atomic-bomb survivor. Blood. 86:1995;2106-2112.
13. Lapidot T., Pflumio F., Doedens M. et al. Cytokine stimulation of multilinea,ge hematopoiesis from immature human cells engrafted in SCID mice. Science. 255:1992;1137-1141.
14. Nolta J.A., Hanley M.B., Kohn D.B. Sustained human hematopoietis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. Blood. 83:1994;3041-3051.
15. Abkowitz J.L., Persik M.T., Shelton G.H. et al. Behavior of hematopoietic stem cells in a large animal. Proc. Natl. Acad. Sci. USA. 92:1995;2031-2035.
16. Jordan C.T., Astle C.M., Zawadzki J. et al. Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. Exp. Hematol. 23:1995;1011-1015.
17. Hodgson G.S., Bradley T.R. Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell? Nature. 281:1979;381-382.
18. Hao Q.L., Thiemann F.T., Petersen D. et al. Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population. Blood. 88:1996;3306-3313.
19. Abkowitz J.L., Catlin S.N., Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat. Med. 2:1996;190-197.
20. Wang J.C., Doedens M., Dick J.E. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood. 89:1997;3919-3924.
21. Zanjani E.D., Ascensao J.L., Tavassoli M. Liver-derived fetal hematopoietic stem cells selectively and preferentially home to the fetal bone marrow. Blood. 81:1993;399-404.
22. Tanigochi H., Toyoshima T., Fukao K. et al. Presence of hematopoietic stem cells in the adult liver. Nat. Med. 2:1996;198-203.
23. Starzl T.E., Murase N., Thomson A. et al. Liver transplants contribute to their own success. Nat. Med. 2:1996;163-165.
24. Collins R.H. Jr, Sackler M., Pitcher C.J. et al. Immune reconstitution with donor-derived memory/effector T cells after orthotopic liver transplantation. Exp. Hematol. 25:1997;147-159.
25. Uchida N., Weissman I.L. Searching for hematopoietic stem cells: evidence that Thy-1.1loLin-Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J. Exp. Med. 175:1992;175-184.
26. Sutherland D.R., Stewart A.K., Keating A. CD34 antigen: molecular features and potential clinicalapplications. Stem. Cells. 11:1993;50-57.
27. Sutherland H.J., Eaves C.J., Eaves A.C. et al. Characterization and partial purlfication of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood. 74:1989;1563-1570.
28. Craig W., Kay R., Cutler R.L. et al. Expression of Thy-1 on human hematopoietic progenitor cells. J. Exp. Med. 177:1993;1331-1342.
29. Sutherland D.R., Yeo E.L., Stewart A.K. et al. Identification of CD34+subsets after glycoprotease selection: engraftment of CD34+Thy-l+Lin- stem cells in fetal sheep. Exp. Hematol. 24:1996;795-806.
30. Lansdorp P.M., Dragowska W. Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purlfied progenitor cells from human bone marrow. J. Exp. Med. 175:1992;1501-1509.
31. Udomsakdi C., Eaves C.J., Sutherland H.J. et al. Separation of functionally distinct subpopulations of primitive human hematopoietic cells using rhodamine-123. Exp. Hematol. 19:1991;338-342.
32. Goodell M.A., Brose K., Paradis G. et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183:1996;1797-1806.
33. Goodell M.A., Rosenzweig M., Kim H. et al. Dye effflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 3:1997;1337-1345.
34. Metcalf D. The molecular control of proliferation and differentiation in hemopoietic cells. CR. Acad. Sci. Ser. 316:1993;860-870.
35. Metcalf D., Nicola N.A. Proliferative effects of purlfied granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J. Cell. Physiol. 116:1983;198-206.
36. Metcalf D., Johnson G.R., Burgess A.W. Direct stimulation by purlfied GM-CSF of the proliferation of multipotential and erythroid precursor cells. Blood. 55:1980;138-147.
37. Sieff C.A., Niemeyer C.M., Nathan D.G. et al. Stimulation of hunian hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3. J. Clin. Invest. 80:1987;818-823.
38. Kobayashi M., Laver J.H., Kato T. et al. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood. 88:1996;429-436.
39. Shah A.J., Smogorzewska E.M., Hannum C. et al. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Blood. 87:1996;3563-3570.
40. Petzer A.L., Zandstra P.W., Piret J.M. et al. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin. J. Exp. Med. 183:1996;2551-2558.
41. Zandstra P.W., Conneally E., Petzer A.L. et al. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc. Natl. Acad. Sci. USA. 94:1997;4698-46703.
42. Piacibello W., Sanavio F., Garetto L. et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood. 89:1997;2644-2653.
43. Larochelle A., Vormoor J., Hanenberg H. et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat. Med. 2:1996;1329-1337.
44. Srour E.F., Zanjani E.D., Cornetta K. et al. Persistence of human multilineage, selfrenewing lymphohematopoietic stem cells in chimeric sheep. Blood. 82:1993;3333-3342.
45. Omori F, Lutzko C, Abrams-Ogg A, et al. Adoptive transfer of genetically modified human hematopoietic stem cells into pre-immune canine fetuses. Exp Hematol 1998 (in press).
46. Almeida-Porada G., Ascensao J.L., Zanjani E.D. The role of sheep stroma in human haemopoiesis in the human/sheep chimaeras. Br. J. Haematol. 93:1996;795-802.
47. Bhatia M., Wang J.C.Y., Kapp U. et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. USA. 94:1997;5320-5325.
48. Bhatia M., Bonnet D., Kapp U. et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J. Exp. Med. 186:1997;619-624.
49. Gan O.I., Murdoch B., Larochelle A. et al. Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood. 90:1997;641-650.
50. Nolta J.A., Dao M.A., Wells S. et al. Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc. Natl. Acad. Sci. USA. 93:1996;2414-2419.
51. Dao M.A., Yu X.J., Nolta J.A. Clonal diversity of primitive human hematopoietic progenitors following retroviral marking and long-term engraftment in immune-deficient mice. Exp. Hematol. 25:1997;1357-1366.
52. Zanjani E.D., Srour E.F., Hoffman R. Retention of long-term repopulating ability of xenogeneic transplanted purlfied adult human bone marrow hematopoietic stem cells in sheep. J. Lab. Clin. Med. 126:1995;24-28.
53. Civin C.I., Almeida-Porada G., Lee M.J. et al. Sustained, retransplantable, multilineage engraftment of highly purlfied adult human bone marrow stem cells in vivo. Blood. 88:1996;4102-4109.
54. Kawashima I., Zanjani E.D., Almaida-Porada G. et al. CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells. Blood. 87:1996;4136-4142.
55. Temin H. Origin and general nature of retroviruses. Levy J.A. The retroviridae. 1992;1-18 Plenum Press, New York.
56. Varmus H.E., Padgett T., Heasley S. et al. Cellular functions are required for the synthesis and integration of avian sarcoma virus-specific DNA. Cell. 11:1977;307-319.
57. Miller D.G., Adam M.A., Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10:1990;4239-4242.
58. Roe T., Reynolds T.C., Yu G. et al. Integration of murine leukemia virus DNA depends on mitosis. EMBO. J. 12:1993;2099-2108.
59. Hajihosseini M., Iavachev L., Price J. Evidence that retroviruses integrate into postreplication host DNA. EMBO. J. 12:1993;4969-4974.
60. Gunzburg W.H., Salmons B. Development of retroviral vectors as safe, targeted gene delivery systems. J. Mol. Med. 74:1996;171-182.
61. Bender M.A., Palmer T.D., Gelinas R.E. et al. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J. Virol. 61:1987;1639-1646.
62. Armentano D., Yu S.F., Kantoff P.W. et al. Effect of internal viral sequences on the utility of retroviral vectors. J. Virol. 61:1987;1647-1650.
63. Adam M.A., Miller A.D. Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions. J. Virol. 62:1988;3802-3806.
64. Miller A.D. Retroviral vectors. Curr. Top. Microbiol. Immunol. 158:1992;1-24.
65. Hawley R.G., Lieu F.H., Fong A.Z. et al. Versatile retroviral vectors for potential use in gene therapy. Gen. Ther. 1:1994;136-138.
66. Miller A.D. Retrovirus packaging cells. Hum. Gene. Ther. 1:1990;5-14.
67. Danos O., Mulligan R.C. Safe and effficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA. 85:1988;6460-6464.
68. Markowitz D., Goff S., Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 167:1988;400-406.
69. Miller A.D., Garcia J.V., von Suhr N. et al. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65:1991;2220-2224.
70. Rollins S.A., Birks C.W., Setter E. et al. Retroviral vector producer cell killing in human serum is mediated by natural antibody and complement: strategies for evading the humoral immune response. Hum. Gene. Ther. 7:1996;619-626.
71. Cornetta K., Moen R.C., Culver K. et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene. Ther. 1:1990;15-30.
72. Cornetta K., Morgan R.A., Gillio A. et al. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum. Gene. Ther. 2:1991;215-219.
73. Cornetta K., Morgan R.A., Anderson W.F. Safety issues related to retroviral-mediated gene transfer in humans. Hum. Gene. Ther. 2:1991;5-14.
74. Graham F.L. Adenovirus vectors for gene expression and gene therapy. Transfus. Sci. 17:1996;15-27.
75. Neering S.J., Hardy S.F., Minamoto D. et al. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood. 88:1996;1147-1155.
76. Watanabe T., Kuszynski C., Ino K. et al. Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors [see comments]. Blood. 87:1996;5032-5039.
77. Wroblewski JM, Lay LT, Meeker TC. Adenoviral vectors in hematology: purging, stem cell gene transfer, or both. Blood 1997;89.
78. Ilan Y., Droguett G., Chowdhury N.R. et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. USA. 94:1997;2587-2592.
79. Chen H.H., Mack L.M., Kelly R. et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA. 94:1997;1645-1650.
80. Parks R.J., Chen L., Anton M. et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA. 93:1996;13565-13570.
81. Kotin R.M. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene. Ther. 5:1994;793-801.
82. Chatterjee S., Wong K.K. Adeno-associated virus vectors for gene therapy of the hematopoietic system. Curr. Top. Microbiol. Immunol. 218:1996;61-73.
83. Ogniben E., Haas R. Adeno-associated virus type 2 vector for transduction of hematopoietic cells. Recent. Results. Cancer. Res. 144:1998;86-92.
84. Kotin R.M., Menninger J.C., Ward D.C. et al. Mapping and direct visualization of a regionspecific viral DNA integration site on chromosome 19q13-qter. Genomics. 10:1991;831-834.
85. Samulski R.J., Zhu X., Xiao X. et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO. J. 10:1991;3941-3950.
86. Chiorini J.A., Wiener S.M., Yang L. et al. The roles of AAV Rep proteins in gene expression and targeted integration. Curr. Top. Microbiol. Immunol. 218:1996;25-33.
87. Alexander I.E., Russell D.W., Miller A.D. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results. Hum. Gene. Ther. 8:1997;1911-1920.
88. Russell D.W., Alexander I.E., Miller A.D. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA. 92:1995;5719-5723.
89. Ponnazhagan S., Yoder M.C., Srivastava A. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo. J. Virol. 71:1997;3098-3104.
90. Fisher-Adams G., Wong K.K. Jr, Podsakoff G. et al. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood. 88:1996;492-504.
91. Fouillard L. Physical method for gene transfer: an alternative to viruses. Hematol. Cell. Ther. 38:1996;214-216.
92. Matthews K.E., Dev S.B., Toneguzzo F. et al. Electroporation for gene therapy. Methods. Mol. Biol. 48:1995;273-280.
93. Marit G., Cao Y., Froussard P. et al. Increased liposome-mediated gene transfer into human CD34+ hemtopoietic cells by adhesion to stromal or fibroblast cell line monolayers. Blood. 90 (Suppl 1):1997;415b.
94. Miller A.D., Rosman G.J. Improved retroviral vectors for gene transfer and expression. Biotech. 7:1989;980-982.
95. Emerman M., Temin H.M. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell. Biol. 6:1986;792-800.
96. Bowtell D.D., Cory S., Johnson G.R. et al. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J. Virol. 62:1988;2464-2473.
97. Emerman M., Temin H.M. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell. 39:1984;449-467.
98. Emerman M., Temin H.M. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic. Acids. Res. 14:1986;9381-9396.
99. Challita P.M., Kohn D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. USA. 91:1994;2567-2571.
100. Qin L., Ding Y., Pahud D.R. et al. Promoter attenuation in gene therapy: interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum. Gene. Ther. 8:1997;2019-2029.
101. Riviere I., Brose K., Mulligan R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA. 92:1995;6733-6737.
102. Yan X.Q., Lacey D., Fletcher F. et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 86:1995;4025-4033.
103. Hawley R.G., Hawley T.S., Fong A.Z. et al. Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. Proc. Natl. Acad. Sci. USA. 93:1996;10297-10302.
104. Conneally E., Bardy P., Eaves C.J. et al. Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviralmediated gene transfer. Blood. 87:1996;456-464.
105. Kaptein L.C., Van Beusechem V.W., Riviere I. et al. Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells. Hum. Gene. Ther. 8:1997;1605-1610.
106. Pawlink R., Eaves C.J., Humphries R.K. Sustained high-level reconstitution ofthe hematopoietic system by preselected hematopoietic cells expressing a transduced cellsurface antigen. Hum. Gene. Ther. 8:1997;1595-1604.
107. Robbins P.B., Yu X.J., Skelton D.M. et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J. Virol. 71:1997;9466-9474.
108. Malik P., Krall W.j, Yu X.j et al. Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Blood. 86:1995;2993-3005.
109. Harms J.S., Splitter G.A. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene. Ther. 6:1995;1291-1297.
110. Ellis J., Tan-Un K.C., Harper A. et al. A dominant chromatin-opening activity in 5′ hypersensitive site 3 of the human beta-globin locus control region. EMBO. J. 15:1996;562-568.
111. Wang Y, O'Malley BW, Tsai SY. Inducible system designed for future gene therapy. Methods Mol Biol 63:401-413, 1997.
112. Williams D.A., Lemischka I.R., Nathan D.G. et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature. 310:1984;476-480.
113. Dick J.E., Magli M., Huszar D. et al. Introduction of a selectable gene into prhmitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell. 42:1985;71-79.
114. Eglitis M.A., Kantoff P., Gilboa E. et al. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science. 230:1985;1395-1398.
115. Lemischka I.R., Raulet D.H., Mulligan R.C. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell. 45:1986;917-927.
116. Bodine D.M., Moritz T., Donahue R.E. et al. Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells. Blood. 82:1993;1975-1980.
117. Dunbar C.E., Seidel N.E., Doren S. et al. Improved retroviral gene transfer into murine and rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc. Natl. Acad. Sci. USA. 93:1996;11871-11876.
118. Kantoff P.W., Gillio A.P., McLachlin J.R. et al. Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. J. Exp. Med. 166:1987;219-234.
119. Stead R.B., Kwok W.W., Storb R. et al. Canine model for gene therapy: inefficient gene expression in dogs reconstituted with autologous marrow infected with retroviral vectors. Blood. 71:1988;742-747.
120. Lothrop C.D.J., al-Lebban Z.S., Niemeyer G.P. et al. Expression of a foreign gene in cats reconstituted with retroviral vector infected autologous bone marrow. Blood. 78:1991;237-245.
121. Wieder R., Cornetta K., Kessler S.W. et al. Increased efficiency of retroviral-mediated gene transfer and expression in primate bone marrow progenitors after 5-fluorouracil-induced hematopoietic suppression and recovery. Blood. 77:1991;448-455.
122. Schuening F.G., Kawahara K., Miller A.D. et al. Retrovirus-mediated gene transduction into long-term repopulating marrow cells of dogs. Blood. 78:1991;2568-2576.
123. van Beusechem V.W., Bart-Baumeister J.A., Hoogerbrugge P.M. et al. Influence of interleukin-3, interleukin-6, and stem cell factor on retroviral transduction of rhesus monkey CD34+ hematopoietic progenitor cells measured in vitro and in vivo. Gene. Ther. 2:1995;245-255.
124. Xu L.C., Kluepfel-Stahl S., Blanco M. et al. Growth factors and stromal support generate very efficient retroviral transduction of peripheral blood CD34+ cells from Gaucher patients. Blood. 86:1995;141-146.
125. Van Beusechem V.W., Bart-Baumeister J.A., Bakx T.A. et al. Gene transfer into nonhuman primate CD34+CD11b- bone marrow progenitor cells capable of repopulating lymphoid and myeloid lineages. Hum. Gene. Ther. 5:1994;295-305.
126. Kiem H.P., Darovsky B., von Kalle C. et al. Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells. Blood. 83:1995;1467-1473.
127. Kiem H.P., Darovsky B., Von Kalle C. et al. Long-term persistence of canine hematopoietic cells genetically marked by retrovirus vectors. Hum. Gene. Ther. 7:1995;89-96.
128. Moore K.A., Deisseroth A.B., Reading C.L. et al. Stromal support enhances cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. Blood. 79:1992;1393-1399.
129. Wells S., Malik P., Pensiero M. et al. The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCICs) from the bone marrow of a patient with Gaucher disease. Gene. Ther. 2:1995;512-520.
130. Carter R.F., Abrams-Ogg A.C., Dick J.E. et al. Autologous transplantation of canine longterm marrow culture cells genetically marked by retroviral vectors. Blood. 79:1992;356-364.
131. Bienzle D., Abrams-Ogg A.C., Kruth S.A. et al. Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation. Proc. Natl. Acad. Sci. USA. 91:1994;350-354.
132. Parente M.K., Wolfe J.H. Production of increased titer retrovirus vectors from stable producer cell lines by superinfection and concentration. Gene. Ther. 3:1996;756-760.
133. Kaptein L.C., Greijer A.K., Valerio D. et al. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene. Ther. 4:1997;172-176.
134. Rill D.R., Moen R.C., Buschle M. et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood. 79:1992;2694-2700.
135. Brenner M.K., Rill D.R., Moen R.C. et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85-86.
136. Brenner M.K., Rill D.R., Holladay M.S. et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 342:1993;1134-1137.
137. Brenner M.K., Krance R., Heslop H.E. et al. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in fir.st complete remission. Hum. Gene. Ther. 5:1994;481-499.
138. Rill D.R., Holliday M., Heslop H.E. et al. Long term transgene expression by human hemopoietic cells in vivo. Blood. 90:1997;405a.
139. Dunbar C.E., Cottler-Fox M., O'Shaughnessy J.A. et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 85:1995;3048-3057.
140. Stewart AK, Nanji S, Ruedy C, et al. Gene marked long term culture cells contribute at low levels to hematopoiesis after autologous transplant. 1998 (submitted for publication).
141. Karlsson S. Gene therapy of haematopoietic cells. J. Intern. Med. Suppl. 740:1997;95-99.
142. Whitley C.B., Belani K.G., Chang P.N. et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am. J. Med. Genet. 46:1993;209-218.
143. Peters C., Balthazor M., Shapiro E.G. et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 87:1996;4894-4902.
144. Phipps S., Mulhern R. Developmental outcome of unrelated donor bone marrow transplantation in children with Hurler syndrome. Blood. 89:1997;732-734.
145. Shull R.M., Munger R.J., Spellacy E. et al. Canine α-L-iduronidase deficiency. A model of mucopolysaccharidosis I. Am. J. Path. 109:1982;244-248.
146. Shull R.M., Helman R.G., Spellacy E. et al. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am. J. Pathol. 114:1984;487-495.
147. Shull R.M., Lu X., Dube I. et al. Humoral immune response limits gene therapy in canine MPS I. Blood. 88:1996;377-379.
148. Lutzko C., Kruth S., Abrams-Ogg A. et al. Gene therapy for an enzyme deficiency state is abrogated by immune responses to gene modified hematopoietic stem cells. Blood. 88 (Suppl 1):1996;274a.
149. Bordignon C., Notarangelo L.D., Nobili N. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 270:1995;470-475.
150. Kohn D.B., Weinberg K.I., Nolta J.A. et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med. 1:1995;1017-1023.
151. Hoogerbrugge P.M., van Beusechem V.W., Fischer A. et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene. Ther. 3:1996;179-183.
152. Onodera M., Ariga T., Kawamura N. et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood. 91:1998;30-36.
153. Kohn D.B., Weinberg K.I., Shigeoka A. et al. PEG-ADA reductioh in recipeints of ADA gene-transduced autologous umbilical cord blood CD34+ cells. Blood. 90:1997;404a.
154. Dunbar C.E., Kohn D.B., Schiffman R. et al. Retroviral gene transfer of the glucocerebrosidase gene into PB of BM CD34+ cells from patients with Gauscher disease: Results from a clincial trial. Blood. 90:1997;237a.
155. Barranger J.A., Rice E., Sansieri C. et al. Transfer of the glucocerebrosidase gene to CD34 cells and their autologous tranasplantation in patients with Guacher disease. Blood. 90:1997;405a.
156. Ku H., Yonemura Y., Kaushansky K. et al. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood. 97:1996;4544-4551.
157. Luens K.M., Travis M.A., Chen B.P. et al. Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-l+Lin- cells with preserved ability to engraft SCID-hu bone. Blood. 91:1998;1206-1215.
158. Nolta J.A., Smogorzewska E.M., Kohn D.B. Analysis of optimal conditions for retroviralmediated transduction of primitive human hematopoietic cells. Blood. 86:1995;101-110.
159. Tisdale J.F., Sellers S., Hanazono Y. et al. Clinically-relevant levels of retroviral gene transfer in primates using Fl-t3 ligand and autolgous stroma. Blood Suppl. 88:1997;236a.
160. Bunnell B.A., Muul L.M., Donahue R.E. et al. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA. 92:1995;7739-7743.
161. Movassagh M., Desmyter C., Baillou C. et al. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum. Gene. Ther. 9:1998;225-234.
162. Chuck A.S., Clarke M.F., Palsson B.O. Retroviral infection is limited by Brownian motion. Hum. Gene. Ther. 7:1996;1527-1534.
163. Chuck A.S., Palsson B.O. Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. Hum. Gene. Ther. 7:1996;743-750.
164. Eipers P.G., Krauss J.C., Palsson B.O. et al. Retroviral-mediated gene transfer in human bone marrow cells growth in continuous perfusion culture vessels. Blood. 86:1995;3754-3762.
165. Bertolini F., Battaglia M., Corsini C. et al. Engineered stromal layers and continuous flow culture enhance multidrug resistance gene transfer in hematopoietic progenitors. Cancer. Res. 56:1996;2566-2572.
166. Hanenberg H., Xiao X.L., Dilloo D. et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2:1996;876.
167. Moritz T., Dutt P., Xiao X. et al. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood. 88:1996;855-862.
168. Kiem H.-P., Morris J., Heyward S. et al. Gene transfer into babbon hematopoieti repopulating cells using recombinant human fibronectin fragment CH-296. Blood. 90:1997;236a.
169. Weiss R.A., Tailor C.S. Retrovirus receptors. Cell. 82:1995;531-533.
170. Miller A.D., Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6:1986;2895-2902.
171. Kavanaugh M.P., Miller D.G., Zhang W. et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc. Natl. Acad. Sci. USA. 91:1994;7071-7075.
172. Orlic D., Girard L.J., Jordan C.T. et al. The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc. Natl. Acad. Sci. USA. 93:1996;11097-11102.
173. Kozak S.L., Siess D.C., Kavanaugh M.P. et al. The envelope glycoprotein of an amphotropic murine retrovirus binds specifically to the cellular receptor/phosphate transporter of susceptible species. J. Virol. 69:1995;3433-3440.
174. Orlic D., Girard L.J., Anderson S.M. et al. Identification of human and mouse hematopoietic stem cell populations expressing high levels of mRNA encoding retrovirus receptors [In Process Citation]. Blood. 91:1998;3247-3254.
175. Conneally E., Eaves C.J., Humphries R.K. Efficient retroviral-mediated gene transfer to human cord blood stem cells with In vivo repopulating potential [In Process Citation]. Blood. 91:1998;3487-3493.
176. Lieber A., Vrancken Peeters M.J., Kay M.A. Adenovirus-mediated transfer of the amphotropic retrovirus receptor cDNA increases retroviral transduction in cultured cells. Hum. Gene. Ther. 6:1995;5-11.
177. Qing K., Bachelot T., Mukherjee P. et al. Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells. J. Virol. 71:1997;5663-5667.
178. von Kalle C., Kiem H.P., Goehle S. et al. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood. 84:1994;2890-2897.
179. Glimm H., Kiem H.P., Darovsky B. et al. Efficient gene transfer in primitive CD34+/CD38lo human bone marrow cells reselected after long term exposure to GALV-pseudotyped retroviral vector. Hum. Gene. Ther. 8:1997;2079-2086.
180. Kiem H.P., Heyward S., Winkler A. et al. Gene transfer into marrow repopulating cells:comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood. 90:1997;4638-4645.
181. Dybing J., Lynch C.M., Hara P. et al. GaLV pseudotyped vectors and cationic lipids transduce human CD34+ cells. Hum. Gene. Ther. 8:1997;1685-1694.
182. Burns J.C., Friedmann T., Driever W. et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA. 90:1993;8033-8037.
183. Chen S.T., Iida A., Guo L. et al. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc. Natl. Acad. Sci. USA. 93:1996;10057-10062.
184. Akkina R.K., Walton R.M., Chen M.L. et al. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70:1996;2581-2585.
185. Agrawal Y.P., Agrawal R.S., Sinclair A.M. et al. Cell-cycle kinetics and VSV-G pseudotyped retrovirus-mediated gene transfer in blood-derived CD34+ cells. Exp. Hematol. 24:1996;738-747.
186. Sinclair A.M., Agrawal Y.P., Elbar E. et al. Interaction of vesicular stomatitis virus-G pseudotyped retrovirus with CD34+ and CD34+CD38- hematopoietic progenitor cells. Gene. Ther. 4:1997;918-927.
187. Lever A.M. HIV and other lentivirus-based vectors. Gene. Ther. 3:1996;470-471.
188. Russell D.W., Miller A.D. Foamy virus vectors. J. Virol. 70:1996;217-222.
189. Poeschla E.M., Wong-Staal F., Looney D.J. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4:1998;354-357.
190. Hirata R.K., Miller A.D., Andrews R.G. et al. Transduction of hematopoietic cells by foamy virus vectors. Blood. 88:1996;3654-3661.
191. Zufferey R., Nagy D., Mandel R.J. et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:1997;871-875.
192. Naldini L., Blomer U., Gallay P. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996;263-267.
193. Naldini L., Blomer U., Gage F.h et al. Efficient transfer, integration, and sustained longterm expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA. 93:1996;11382-11388.
194. Blomer U., Naldini L., Kafri T. et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71:1997;6641-6649.
195. Miyoshi H., Takahashi M., Gage F.H. et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA. 94:1997;10319-10323.
196. Pawliuk R., Kay R., Lansdorp P. et al. Selection of retrovirally transduced hematopoietic cells using CD24 as a marker of gene transfer. Blood. 84:1994;2868-2877.
197. Ruggieri L., Aiuti A., Salomoni M. et al. Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. Hum. Gene. Ther. 8:1997;1611-1623.
198. Bauer T.R. Jr, Hickstein D.D. Transduction of human hematopoietic cells and cell lines using a retroviral vector containing a modified murine CD4 reporter gene. Hum. Gene. Ther. 8:1997;243-252.
199. Emmons R.V., Doren S., Zujewski J. et al. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for 6 h without growth factors or on autologous stroma does not improve marking effciency assessed in vivo. Blood. 89:1997;4040-4046.